$TLX News

Telix Pharmaceuticals Signs MoU With United Imaging Healthcare North America To Evaluate A U.S. Research Collaboration On Advancing Integrated Theranostics Solutions

Is Telix (ASX:TLX) Quietly Assembling a Connected Oncology Platform That Reshapes Its Moat?

Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences

Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up

Telix Pharmaceuticals' IPAX-2 Study Of TLX101-Tx Completes Patient Enrolment; Maximum Dose Reached With No Dose-limiting Toxicities Observed; TLX101-Tx Is Also The Subject Of A Pivotal Trial, IPAX BrIGHT, Which Is Actively Dosing Patients With Recurrent Glioblastoma

Telix Pharmaceuticals' TLX250-Px PET/CT Demonstrates High Predictive Accuracy Across All Renal Cancer Subtypes In Phase 3 ZIRCON Trial Analysis

Telix Pharmaceuticals Announces Dosimetry Results From Phase 2 Trial For Metastatic Castration-Resistant Prostate Cancer Treatment TLX597-Tx At International Prostate Cancer Symposium

Telix Pharmaceuticals To Present Safety And Tolerability Data From The ProstACT Global Phase 3 Study At ASCO 2026

Reported Earlier, Telix Pharmaceuticals Doses First Patient In Pivotal Phase 3 IPAX BrIGHT Trial Of TLX101-Tx For Recurrent Glioblastoma At Austin Health In Melbourne

Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Telix Pharmaceuticals shares are trading higher after the company announced a collaboration with Regeneron Pharmaceuticals to jointly develop and commercialize next generation radiopharmaceutical therapies.

HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady

Telix Pharmaceuticals shares are trading higher after the company announced the FDA accepted its resubmitted New Drug Application for TLX101-Px.

Reported Earlier, Telix Pharmaceuticals Receives FDA Acceptance Of NDA Resubmission For TLX101-Px Pixclara, An Investigational PET Agent For Glioma Brain Cancer Imaging

Telix Pharmaceuticals: Solid Q1 As Pipeline And PSMA Franchise Drive Outlook

Why Is Telix Pharma Stock Soaring Tuesday?

Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Telix Pharmaceuticals shares are trading higher after the company reported a quarter-over-quarter increase in Q1 revenue results.

HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target